

## POSTER PRESENTATION

## Open Access

# Predictors of long term outcomes of IgA nephropathy

U Kabir\*, T Rahman, D Connaughton, P Conlon

From International Conference for Healthcare and Medical Students 2011  
Dublin, Ireland. 4-5 November 2011

## Introduction

IgA Nephropathy (IgAN) was first described by Berger and Hinglais in 1968. The correlations between clinical as well as histopathological features on presentation and disease progression still remain unclear.

## Aim

To identify the key predictors of long term renal outcomes in IgAN.

## Methods

Two hundred patients with biopsy proven IgAN were selected and their clinical as well as histopathological data was analysed for progression to End-stage renal disease (ESRD).

## Results

98 patients were used as the selected cohort. 21.5% of patients developed ESRD within 5 years and 28.8% within 10 years. Univariate studies showed that interstitial fibrosis, glomerulosclerosis, presence of fibrocellular crescents, proteinuria (g/24hrs) and raised serum creatinine levels at the time of biopsy were significant. (P value of <0.001 and 95% CI considered significant.) In the multifactorial analysis interstitial fibrosis and raised serum creatinine, lost their significance. (P value of <0.05 and 95% CI considered significant.)

## Conclusions

Combination of proteinuria, glomerulosclerosis and fibrocellular crescents may contribute to poor renal outcomes in patients with IgAN. Interstitial fibrosis and raised serum creatinine levels may have solitary effects on disease progression as well.

Published: 9 July 2012

doi:10.1186/1753-6561-6-S4-P50

**Cite this article as:** Kabir et al.: Predictors of long term outcomes of IgA nephropathy. *BMC Proceedings* 2012 **6**(Suppl 4):P50.

Submit your next manuscript to BioMed Central  
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

